Drug intelligence / Profile preview

amlodipine + chlorthalidone + valsartan

Development stage: Phase 1
Lead developer: AJU Pharm
Modality: Small Molecules
Administration: Oral

Overview

AJU-C52H is a fixed-dose combination drug containing amlodipine (a calcium channel blocker), chlorthalidone (a thiazide-like diuretic), and valsartan (an angiotensin II receptor antagonist). It is being developed by Aju Pharm for the treatment of essential hypertension. The combination targets multiple mechanisms involved in blood pressure regulation to provide enhanced antihypertensive efficacy. Clinical trials have reached Phase 3 in South Korea for patients with essential hypertension who are inadequately controlled on other therapies[1][2][6].

Other names: AJU C52HAJU C52LAJU C52

Targets

SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on amlodipine + chlorthalidone + valsartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + chlorthalidone + valsartan.

Explore the full profile